CT imaging of and therapy for inflammatory bowel disease <i>via</i> low molecular weight dextran coated ceria nanoparticles
Derick N. Rosario‐Berríos, Amanda Pang, Katherine J. Mossburg, Johoon Kim, Víctor R. Vázquez Marrero, Seokyoung Yoon, Mahima Gupta, Olivia C. Lenz, Leening P. Liu, Andrea C. Kian, Kálery La Luz Rivera, Sunny Shin, Peter B. Noël, Elizabeth M. Lennon, David P. Cormode
Abstract
CT imaging of mice subjected to dextran sodium sulfate (DSS) colitis showed that Dex-CeNP provided better contrast in the GIT of mice with colitis compared to iopamidol (ISO), with pronounced attenuation in the large intestine and disease- specific retention at 24 h. Additionally, Dex-CeNP significantly decreased Disease Activity Index (DAI) scores, and diminished gastrointestinal bleeding when compared with a currently approved drug, indicating that it is an effective treatment for colitis. Studies also revealed that the Dex-CeNPs were safe and well-excreted following administration. In summary, Dex-CeNP has significant promise as a dual-purpose agent for CT imaging and treatment of IBD.